Juan Palazzo

Thomas Jefferson University — United States

Medicine · Health Sciences

62h-index23.6kcitations382works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(79), Cancer Genomics and Diagnostics(62), Breast Cancer Treatment Studies(52), Breast Lesions and Carcinomas(31), Cancer-related Molecular Pathways(24)

Publications381 total

A Tissue Renewal-Based Mechanism Drives Colon Tumorigenesis
Cancers·2025Open Access
Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
2025Open Access
A Tissue Renewal-Based Mechanism Drives Colon Tumorigenesis
Preprints.org·2025Open Access
The Pathologic Spectrum of Pregnancy- and Lactation–Associated Breast Lesions
Archives of Pathology & Laboratory Medicine·2025Open Access
S2995 Multiple Myeloma Presenting as Gastrointestinal Bleeding From Gastric Amyloidosis: A Case Report
The American Journal of Gastroenterology·2023
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Journal of Clinical Oncology·2023· 148 cited
Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
2023Open Access
Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
2023Open Access
Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
2023Open Access
Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
2023Open Access
Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
2023Open Access
Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
2023Open Access
Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
2023Open Access
Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
2023Open Access
Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
2023Open Access
Figure S7 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
2023Open Access
Supplemental Table 2: Predicted gene targets of the 16 differentially expressed miRNAs from An miRNA Expression Signature for the Human Colonic Stem Cell Niche Distinguishes Malignant from Normal Epithelia
2023Open Access
Supplemental Table 1: differentially expressed miRNAs in CRC vs normal tissue from An miRNA Expression Signature for the Human Colonic Stem Cell Niche Distinguishes Malignant from Normal Epithelia
2023Open Access
Figure S4 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
2023Open Access
Figure S5 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
2023Open Access
page 1 of 20Next →

Frequent Co-authors

Charles M. Perou(7), Philip S. Bernard(6), Raffaele Baffa(6), Joel S. Parker(5), Xiaping He(5), Zhiyuan Hu(5), John F. Quackenbush(5), Michael E. Mullins(4), Andrew B. Nobel(4), Carlo M. Croce(4), Olufunmilayo I. Olopade(4), Massimo Rugge(4), Terry Hyslop(4), Semir Vranić(4), Zoran Gatalica(4), Scott A. Waldman(4), Robert D. Fry(4), J. S. Marron(3), Matthew J. Ellis(3), Chang‐Gong Liu(3)